Ebola

As March comes to an end, we look back at an unprecedented month in infectious disease news.

The last confirmed patient with Ebola was discharged from care on March 4, 2020.

The International Health Regulations Emergency Committee decided today that the Ebola outbreak in the Democratic Republic of the Congo remains a PHEIC.

A new article examines pregnancy outcomes among women who received the rVSV-ZEBOV vaccine in the STRIVE study.

As January comes to an end, we’re looking back at important infectious disease news from the past month.

In this episode, our guests compare the West African Ebola outbreak to the ongoing outbreak in the Democratic Republic of the Congo.

Investigators of a new analysis detail how Ebola case definitions became increasingly complex and discordant during the 6-month period in the countries surrounding the DRC.

The CDC MMWR provides a summary of the Ebola response from August 2018 to November 2019, noting 2196 deaths and consistent challenges in outbreak control due to government mistrust and ongoing armed conflict.

From Ebola to measles to Salmonella, these were the top 9 infectious disease outbreaks of 2019.

Ervebo has been approved for the prevention of Ebola virus disease, caused by Zaire ebolavirus in individuals 18 years of age and older.

Ebola vaccines could be given as an emergency intervention to individuals exposed to the virus.

The PALM trial evaluated the safety and efficacy of several experimental treatments for Ebola in the Democratic Republic of Congo.

Investigators now think that Ebola prevention methods should be a top priority moving forward.

Prequalification status indicates that the vaccine meets the WHO’s standard for efficacy, safety, and quality.

Since 2014 NYC Health + Hospitals has worked to maintain preparedness against diseases like Ebola.

Leaders from the WHO and various impacted countries met to assess the risks of the Ebola outbreak in the Democratic Republic of the Congo and the future of the outbreak response.

Scientists from the National Institutes of Health are hopeful that diluting a dose of the VSV vaccine could be efficacious and stretch vaccine supplies even further.

A patient was evaluated for Ebola in a Swedish hospital. Here's what we should take away from it.

The analysis of the survey responses found a statistically significant association in denial of the biomedical discourse and dissatisfaction or mistrust of the Ebola response as indicators of social resistance.

In part 2 of our Q&A with Fair, we talk about the challenges ahead in the fight against Ebola in the Democratic Republic of the Congo.

In part 1 of our Q&A with Fair, we talk about his background, education, and experience, and also how the outbreak response to the current Ebola outbreak in the DRC differs from traditional disaster response.

The vaccine, manufactured by Johnson & Johnson, is administered in 2 doses, 56 days apart and will be used in areas that are not experiencing active transmission.

In this outbreak, 18% of Ebola cases have been tied to health care transmission. How can we prevent this from continuing?

The target action date for the V920 investigational Ebola vaccine is set for March 14, 2020.

Investigators observed that, when compared with the general population of Guinea, survivors of Ebola had a 5-fold increased risk of mortality over a mean of 1 year of follow-up after discharge.